This site is intended for Great Britain healthcare professionals only
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Menu
Close
Information on how to access Cibinqo®▼ (abrocitinib) prescribing information and adverse event reporting can be found at the bottom of the page.
Updated Safety Recommendation - Abrocitinib should only be used if no suitable treatment alternatives are available in patients: 65 years of age and older, patients with history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past long-time smokers), patients with malignancy risk factors (e.g. current malignancy or history of malignancy). (Cibinqo Summary of Product Characteristics)
Cibinqo 200 mg and 100 mg is a once-daily oral treatment
The dose may be decreased or increased based on tolerability and efficacy.
Cibinqo can be used with or without medicated topical therapies for atopic dermatitis
Cibinqo can be taken with or without food at approximately the same time each day
Tablets should be swallowed whole with water and should not be split, crushed or chewed
• Hypersensitivity to the active substance or to any of the excipients.
• Active serious systemic infections, including tuberculosis
• Severe hepatic impairment
• Pregnancy and breast-feeding
Method of administration:1 Cibinqo is taken orally once daily with or without food at approximately the same time each day. In patients who experience nausea, taking Cibinqo with food may improve nausea. Tablets should be swallowed whole with water and should not be split, crushed or chewed because these methods have not been studied in clinical trials. |
Cibinqo is a once-daily oral treatment:1
|
For patients 65 years of age and older, the recommended dose is 100 mg once daily.1 |
The lowest effective dose for maintenance should be considered1 |
Cibinqo can be used with or without medicated topical therapies for atopic dermatitis1 |
Discontinuation of treatment should be considered in patients who show no evidence of therapeutic benefit after 12 weeks. Some patients with initial partial response may subsequently improve with continued treatment beyond 12 weeks.1 |
Treatment should not be initiated in patients with a platelet count <150 x 103/mm3, an absolute lymphocyte count (ALC) <0.5 x 103/mm3, an absolute neutrophil count (ANC) <1 x 103/mm3, or a haemoglobin value <8 g/dL1 |
Dose interruption1
If a patient develops a serious infection, sepsis or opportunistic infection, dose interruption should be considered until the infection is controlled. Interruption of dosing may be needed for management of laboratory abnormalities. |
Missed doses1 If a dose is missed, patients should be advised to take the dose as soon as possible unless it is less than 12 hours before the next dose, in which case the patient should not take the missed dose. Thereafter, dosing should be resumed at the regular scheduled time. |
Interactions1 In patients receiving strong inhibitors of cytochrome P450 (CYP) 2C19 (e.g. fluvoxamine, fluconazole, fluoxetine and ticlopidine), the recommended starting dose of Cibinqo should be reduced by half to 100 mg or 50 mg once daily. The use of Cibinqo is not recommended concomitantly with moderate or strong inducers of CYP2C19/CYP2C9 enzymes (e.g. rifampicin, apalutamide, efavirenz, enzalutamide, phenytoin). See the Summary of Product Characteristics for full information. |
Mild impairment (eGFR 60 to <90 mL/min) | Moderate impairment (eGFR 30 to <60 mL/min) | Severe impairment (eGFR <30 mL/min) |
---|---|---|
No dose adjustment required | The recommended dose of Cibinqo should be reduced by half to 100 mg or 50 mg once daily | 50 mg once daily is the recommended starting dose. The maximum daily dose is 100 mg |
Cibinqo has not been studied in patients with end-stage renal disease (ESRD) on renal replacement therapy.1
Mild impairment (Child Pugh A) | Moderate impairment (Child Pugh B) | Severe impairment (Child Pugh C) |
---|---|---|
No dose adjustment required | No dose adjustment required | Not studied, must not be used (contraindication) |
Example
Learn more about monitoring patients on Cibinqo.
Access resources to help you support your patients on Cibinqo.
CYP=cytochrome P450; eGFR=estimated glomerular filtration rate; MAO=monoamine oxidase; P-gp=P glycoprotein.
References:
Cibinqo Risk Minimisation Programme (RMP) materials, including a Patient Card and Prescriber Brochure, are available from https://www.medicines.org.uk/emc/product/12874/rmms. Patients treated with Cibinqo should be given the Patient Card.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021